SHP1 Antibody - #DF6414

(1)   (3)  
Product: SHP1 Antibody
Catalog: DF6414
Description: Rabbit polyclonal antibody to SHP1
Application: WB IHC IF/ICC
Cited expt.: WB, IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Sheep, Rabbit, Dog
Mol.Wt.: 65kDa; 68kD(Calculated).
Uniprot: P29350
RRID: AB_2838377

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(88%), Bovine(88%), Horse(88%), Sheep(88%), Rabbit(100%), Dog(88%)
Clonality:
Polyclonal
Specificity:
SHP1 Antibody detects endogenous levels of total SHP1.
RRID:
AB_2838377
Cite Format: Affinity Biosciences Cat# DF6414, RRID:AB_2838377.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

70Z-SHP; EC 3.1.3.48; HCP; HCPH; Hematopoietic cell phosphatase; Hematopoietic cell protein tyrosine phosphatase; Hematopoietic cell protein-tyrosine phosphatase; HPTP1C; Protein tyrosine phosphatase 1C; Protein tyrosine phosphatase non receptor type 6; Protein tyrosine phosphatase SHP1; Protein-tyrosine phosphatase 1C; protein-tyrosine phosphatase SHP 1; Protein-tyrosine phosphatase SHP-1; PTN6_HUMAN; PTP 1C; PTP-1C; PTP1C; Ptpn6; SH PTP 1; SH PTP1; SH-PTP1; SHP 1; SHP 1L; SHP1; SHP1L; tyrosine protein phosphatase non receptor type 6; Tyrosine-protein phosphatase non-receptor type 6;

Immunogens

Immunogen:

A synthesized peptide derived from human SHP1, corresponding to a region within C-terminal amino acids.

Uniprot:

P29350(PTN6_HUMAN) >>Visit HPA database.

Gene(ID):
PTPN6(5777)
Expression:
P29350 PTN6_HUMAN:

Isoform 1 is expressed in hematopoietic cells. Isoform 2 is expressed in non-hematopoietic cells.

Description:
SHP-1 (PTPN6) is a non-receptor protein tyrosine phosphatase that is expressed primarily in hematopoietic cells. The enzyme is composed of two SH2 domains, a tyrosine phosphatase catalytic domain, and a carboxy-terminal regulatory domain (1). SHP-1 removes phosphates from target proteins to downregulate several tyrosine kinase-regulated pathways. In hematopoietic cells, the amino-terminal SH2 domain of SHP-1 binds to tyrosine phosphorylated erythropoietin receptors (EpoR) to negatively regulate hematopoietic growth (2). Overexpression of SHP-1 in epithelial cells results in dephosphorylation of the Ros receptor tyrosine kinase and subsequent downregulation of Ros-dependent cell proliferation and transformation (3). Following ligand binding in myeloid cells, SHP-1 associates with the IL-3R β chain and downregulates IL-3-induced tyrosine phosphorylation and cell proliferation (4). Because SHP-1 downregulates various proliferation pathways, SHP-1 is considered a potential tumor suppressor and angiogenesis regulator (5,6).
Sequence:
MVRWFHRDLSGLDAETLLKGRGVHGSFLARPSRKNQGDFSLSVRVGDQVTHIRIQNSGDFYDLYGGEKFATLTELVEYYTQQQGVLQDRDGTIIHLKYPLNCSDPTSERWYHGHMSGGQAETLLQAKGEPWTFLVRESLSQPGDFVLSVLSDQPKAGPGSPLRVTHIKVMCEGGRYTVGGLETFDSLTDLVEHFKKTGIEEASGAFVYLRQPYYATRVNAADIENRVLELNKKQESEDTAKAGFWEEFESLQKQEVKNLHQRLEGQRPENKGKNRYKNILPFDHSRVILQGRDSNIPGSDYINANYIKNQLLGPDENAKTYIASQGCLEATVNDFWQMAWQENSRVIVMTTREVEKGRNKCVPYWPEVGMQRAYGPYSVTNCGEHDTTEYKLRTLQVSPLDNGDLIREIWHYQYLSWPDHGVPSEPGGVLSFLDQINQRQESLPHAGPIIVHCSAGIGRTGTIIVIDMLMENISTKGLDCDIDIQKTIQMVRAQRSGMVQTEAQYKFIYVAIAQFIETTKKKLEVLQSQKGQESEYGNITYPPAMKNAHAKASRTSSKHKEDVYENLHTKNKREEKVKKQRSADKEKSKGSLKRK

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Rabbit
100
Pig
88
Horse
88
Bovine
88
Sheep
88
Dog
88
Xenopus
0
Zebrafish
0
Chicken
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Research Backgrounds

Function:

Modulates signaling by tyrosine phosphorylated cell surface receptors such as KIT and the EGF receptor/EGFR. The SH2 regions may interact with other cellular components to modulate its own phosphatase activity against interacting substrates. Together with MTUS1, induces UBE2V2 expression upon angiotensin II stimulation. Plays a key role in hematopoiesis.

PTMs:

Phosphorylated on tyrosine residues. Binding of KITLG/SCF to KIT increases tyrosine phosphorylation (By similarity). Phosphorylation at Tyr-564 enhances phosphatase activity.

Subcellular Location:

Cytoplasm. Nucleus.
Note: In neurons, translocates into the nucleus after treatment with angiotensin II (By similarity). Shuttles between the cytoplasm and nucleus via its association with PDPK1.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Isoform 1 is expressed in hematopoietic cells. Isoform 2 is expressed in non-hematopoietic cells.

Family&Domains:

The N-terminal SH2 domain functions as an auto-inhibitory domain, blocking the catalytic domain in the ligand-free close conformation.

Belongs to the protein-tyrosine phosphatase family. Non-receptor class 2 subfamily.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Adherens junction.   (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

References

1). A novel GRK2 inhibitor alleviates experimental arthritis through restraining Th17 cell differentiation. Biomedicine & Pharmacotherapy, 2023 (PubMed: 36399825) [IF=6.9]

Application: IF/ICC    Species: Mouse    Sample: splenic T cells

Fig. 2. CP-25 inhibited Th17 cell differentiation through recovering SHP1 and STAT3 interaction. (A) Representative pSTAT3Tyr705 and STAT3 immunoblotting of splenic lymphocytes from control, Veh, CP-25 or PAR treated CIA mice. (B) Statistic analysis of the ration of pSTAT3Tyr705 against STAT3 in splenic lymphocytes from 4 groups. (C) CD4 was labeled with Alexa Fluor 647 and pSTAT3Tyr705 was labeled with Alexa Fluor 488 in splenic T cells isolated from individual groups of mice. (D) The mean fluorescence intensity (MFI) of pSTAT3Tyr705 was used to indicate the relative expression level of pSTAT3Tyr705 in CD4 positive T cells. (E) SHP1 was labeled with Alexa Fluor 647 and STAT3 was labeled with Alexa Fluor 488 in splenic T cells isolated from treated CIA mouse. (F) The colocalization rate between SHP1 and STAT3 was analyzed. (G) Splenic naïve (CD4+CD62L+) T cells were stimulated with IL-6, IL-21, IL-23, TGF-β for 72 h with or without NSC87877 pretreatment, followed by a 4-hour PMA, BFA and ionomycin induction, and then IL-17A+ positive Th17 cells were sorted. The cells were gated on FSC-SSC dot plot, and then the lymphocytes were gated for analyzing the percentage of Th 17 (CD4+IL-17A+) cells. (H) The percentage of Th17 cells induced by indicated conditions was compared. Data were presented as mean ± SD from 5 mice per group. ** p < 0.01, *** p < 0.001 by one-way ANOVA followed by post hoc Tukey’s test.

Application: WB    Species: Mouse    Sample: splenic T cells

Fig. 3. SHP1 inhibited STAT3 activation in CD4+ T cells in an arrb2 dependent manner. (A) Arrb2 was stained in green and SHP1 was in red in splenic T cells from treated CIA mouse. (B) The MFI of arrb2 in CD4 positive T cells was analyzed. (C) The colocalization rate of SHP1 and arrb2 was calculated. n = 5. (D) Arrb2 in lysate of splenic T cells from treated mice was pulled down and both SHP1 and arrb2 were blotted. (E) The relative intensity of arrb2 bound to SHP1 was compared between individual groups of mice. n = 3. (F) CD4+ T cells isolated from WT or arrb2 null mice were treated with or without IL-6, IL-21, IL-23 and TGF-β, and then SHP1 and STAT3 were labeled. (G) The correlation between SHP1 and STAT3 was determined. n = 6–7. (G) Total and phosphorylated STAT3 at Tyr705 site was detected by flow cytometry in T cells from WT or arrb2-/- mice followed by indicated treatment. Cells only incubated with secondary antibody were set as isotype control to exclude non-specific staining. (H-J) The MFI of pSTAT3, total STAT3 and the ratio of pSTAT3 to total STAT3 was analyzed. n = 5. Data were presented as mean ± SD. * p < 0.05, ** p < 0.01, *** p < 0.001 by one-way ANOVA followed by post hoc Tukey’s test.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.